Market research
BLISSGVS.NSE Bliss GVS Pharma Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 66B
- P/E ratio
- 49.21
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.22
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE416D01022
- Market cap
- 66B
- P/E ratio
- 49.21
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.22
About
About Bliss GVS Pharma Limited
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
Research context
Bliss GVS Pharma Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BLISSGVS.NSE discussion.
5 years, 6 months ago
Bliss GVS Pharma Limited is currently in a long term downtrend where the price is trading 24.1% below its 200 day moving average.
From a valuation standpoint, the stock is 60.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Bliss GVS Pharma Limited's total revenue rose by 11.0% to $2B since the same quarter in the previous year.
Its net income has increased by 7.6% to $256M since the same quarter in the previous year.
Finally, its free cash flow grew by 157.3% to $779M since the same quarter in the previous year.
Based on the above factors, Bliss GVS Pharma Limited gets an overall score of 4/5.